Krka ESG Rating

On 3 December 2025, Krka received a score of 55 (out of 100) in the 2025 S&P Global* Corporate Sustainability Assessment.

The received independent score reaffirms the outlined direction of the Krka Group’s sustainable management practises and ESG governance, where we prioritise our social responsibility and care for the health and well-being of patients. We provide them with access to high-quality, safe and effective medicines produced to the highest standards of good manufacturing practise. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity and transparent operations.

This year, within the Krka Group Development Strategy until 2030, under the three strategic pillars, we have further outlined our commitment to providing uninterrupted access to medicines, developing innovative generic medicines for the treatment of chronic diseases, and value creation so that the positive impacts of our operations reach all Krka stakeholders. In this way, we fulfill Krka’s mission of Living a Healthy Life.

The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group.

*Standard & Poor’s (S&P) is a global leading index provider and data source of independent credit ratings and CSA/ESG scores.